US Bancorp DE Sells 1,839 Shares of LivaNova PLC (NASDAQ:LIVN)

US Bancorp DE lessened its holdings in LivaNova PLC (NASDAQ:LIVN) by 39.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,832 shares of the company’s stock after selling 1,839 shares during the quarter. US Bancorp DE’s holdings in LivaNova were worth $149,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Hexagon Capital Partners LLC grew its stake in shares of LivaNova by 117.8% in the second quarter. Hexagon Capital Partners LLC now owns 684 shares of the company’s stock valued at $37,000 after buying an additional 370 shares in the last quarter. Fifth Third Bancorp grew its position in shares of LivaNova by 97.1% in the 2nd quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock valued at $37,000 after acquiring an additional 332 shares during the period. Lazard Asset Management LLC bought a new position in shares of LivaNova in the 1st quarter valued at about $84,000. Canada Pension Plan Investment Board bought a new stake in shares of LivaNova in the 2nd quarter valued at about $88,000. Finally, Acadian Asset Management LLC acquired a new stake in LivaNova in the 1st quarter valued at about $94,000. Institutional investors own 97.64% of the company’s stock.

LivaNova Stock Down 0.4 %

LIVN opened at $52.10 on Friday. The stock has a fifty day moving average of $51.67 and a 200-day moving average of $52.98. The company has a market capitalization of $2.83 billion, a P/E ratio of 124.05 and a beta of 1.01. LivaNova PLC has a fifty-two week low of $42.75 and a fifty-two week high of $64.47. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Baird R W raised LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 17th. Mizuho reduced their target price on LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a research note on Thursday, October 31st. The Goldman Sachs Group began coverage on LivaNova in a research note on Friday, October 4th. They issued a “buy” rating and a $65.00 price target on the stock. Stifel Nicolaus lifted their price objective on shares of LivaNova from $70.00 to $72.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. Finally, Robert W. Baird increased their price objective on shares of LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $69.17.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.